MPI, Edge Therapeutics to advance therapies for brain disorders

Under the partnership, the companies will combine their skills and expertise with the goal of initiating clinical trials of Edge’s portfolio of therapies that use implantable technology to deliver proven drugs directly to the site of brain injury.

MPI Research will act as Edge’s primary service provider for pharmacologic, analytical, and safety in preclinical testing, and will also provide analytical services for clinical testing.

Edge chief scientific officer and neurosurgeon R. Loch Macdonald said partnering with MPI Research allows Edge to access additional expertise and capabilities on a larger scale, helping to advance the company’s hospital products into clinical trials.

Edge uses a novel, site-specific and sustained release-microparticle technology platform to deliver drugs to the brain for treating neurological conditions.